AdAlta Limited (ASX:1AD) announcement

AdAlta Limited (ASX:1AD) has announced the formation of a Clinical Advisory Board (CAB) and the appointment of an additional adviser for its lead asset AD-214, which is being developed to treat Idiopathic Pulmonary Fibrosis (IPF). These strategic appointments are part of the Company's ongoing preparations for upcoming Phase II clinical trials of AD-214, aiming to build on the positive results observed in Phase I studies.

Executive commentary

Our efforts to develop AD-214 have taken a further significant step forward with the creation of our Clinical Advisory Board and the appointment of a specialist adviser for translational science. As a group, these highly skilled healthcare professionals are not just experts in the treatment of Idiopathic Pulmonary Fibrosis, they are also passionate about advancing therapeutic options for this debilitating disease and collectively have immense experience in delivering IPF clinical trials. We welcome them to AdAlta as the Company looks to advance its development of AD-214.

Summary

AdAlta Limited (ASX:1AD) has appointed a Clinical Advisory Board (CAB) and an additional adviser for its lead asset AD-214, signaling a significant step forward in the development of treatments for Idiopathic Pulmonary Fibrosis (IPF). The newly created CAB, comprising renowned experts in pulmonary medicine and fibrosis, will play a crucial role in guiding AD-214's Phase II clinical trial preparations and ensuring the trial's success. These strategic appointments align with AdAlta's commitment to advancing AD-214 through its next stage of development, aiming to improve outcomes for the more than 500,000 IPF patients worldwide. The Company's ongoing preparations for Phase II trials and the engagement of specialist advisers reflect its dedication to addressing the unmet medical needs in IPF and other fibrotic diseases.